Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma Press Release Oct 25 Written By Kyle Kostesich View designation on FDA.gov Kyle Kostesich
Phosplatin Therapeutics receives US FDA Orphan Drug designation for the use of PT-112 in patients with Thymoma and Thymic Carcinoma Press Release Oct 25 Written By Kyle Kostesich View designation on FDA.gov Kyle Kostesich
